Citeline Podcasts

최근 제프리스 헬스케어 컨퍼런스에서 발표된 제약바이오산업의 생성형인공지능 적용사례에 대한 Scrip 기사를 요약한 내용입니다. https://scrip.citeline.com/SC149412/As-Biopharma-Adopts-Generative-AI-The-People-Element-Is-Crucial-To-Success

Audio roundup of selected biopharma industry content from Scrip over the past business week. In this episode: CAR-Ts and malignancies; comeback for GSK’s Blenrep?; Novartis’s pipeline cull; FGF21 analogs in NASH; and a call to action from the Scrip Awards Lifetime Achievement winner. https://scrip.citeline.com/SC149443/Quick-Listen-Scrips-Five-MustKnow-Things

Pink Sheet reporter and editors discuss the FDA acknowledging reports of malignancies in patients who received CAR-T cell immunotherapies (:35), the agency’s policy for using background music in direct-to-consumer advertising (7:27), and the FDA’s new incoming principal deputy commissioner (13:44). More On These Topics From The Pink Sheet CAR-T Malignancy Reports Could Temper Excitement For Use Beyond Oncology: https://pink.citeline.com/PS149420/CAR-T-Malignancy-Reports-Could-Temper-Excitement-For-Use-Beyond-Oncology Background Music During Risk Segment Of Rx Drug Ads: FDA Explains Its Policy: https://pink.citeline.com/PS149411/Background-Music-During-Risk-Segment-Of-Rx-Drug-Ads-FDA-Explains-Its-Policy US FDA Chief Scientist Bumpus Will Become Principal Deputy Commissioner: https://pink.citeline.com/PS149428/US-FDA-Chief-Scientist-Bumpus-Will-Become-Principal-Deputy-Commissioner

In this podcast, In Vivo speaks to Sara Barrington, CEO of Verici DX. During the discussion, Barrington outlines the current challenges facing patients post-transplant, why current diagnostics are inadequate, and where the overall transplant market is headed, considering the rise of home dialysis and the potential future for xenotransplants.

Audio roundup of selected biopharma industry content from Scrip over the past business week. In this episode: Bayer’s Phase III failure; US group seeks Japan changes; AstraZeneca winning AKT race for now; NASH developments at AASLD; and the Q3 impact of China’s corruption campaign. https://scrip.citeline.com/SC149413/Quick-Listen-Scrips-Five-MustKnow-Things

Datamonitor Healthcare’s Epidemiology team (Ridwaan Ibrahim, Lucia Rodriguez-Garcia, Maya Trivedy, and Asma Ali) discuss the current trends in epidemiology throughout the world, and how epidemiology data is being used to support drug discovery and improve health outcomes. Topics discussed include epidemiology methodologies, Alzheimer’s Disease, non-communicable diseases in Africa, genetic epidemiology, pollution, and increasing cancer rates. Other platforms Apple Podcasts - https://podcasts.apple.com/us/podcast/pharma-intelligence-podcasts/id923189836​ Google Podcasts - https://podcasts.google.com/feed/aHR0cHM6Ly9mZWVkcy5zb3VuZGNsb3VkLmNvbS91c2Vycy9zb3VuZGNsb3VkOnVzZXJzOjEwNjU1NDkyOC9zb3VuZHMucnNz​​ TuneIn - https://tunein.com/podcasts/Business--Economics-Podcasts/Pharma-Intelligence-Podcasts-p1140128/​ Spotify Podcasts - https://open.spotify.com/show/3DTc3eIh4xI6pVOd6DdO67

In accepting Scrip’s Lifetime Achievement Award, Ovid Therapeutics’ CEO called on pharma to show responsible leadership and live up to its potential to do good for society.

Brian Yang and Dexter Yan discuss the FDA approval of Chinese PD-1, Sanofi BioMap AI deal, Third quarter earnings and Biden-Xi Summit and US-China regulatory dialogue.

In this podcast, Medtech Insight speaks to Andy Molnar, CEO of the digital therapeutics alliance; Joel Morse, CEO and co-founder of Curavit and Owen McCarthy, CEO and co-founder of MedRhythyms. The trio discuss the current situation surrounding digital therapeutics, and where they believe they are headed in the coming years.

In this month’s Digital Health Roundup, Medtech Insight’s Marion Webb highlights interviews with Abbott’s head of Lingo Biowearables and top executives at Twin Health. Reed Miller provides an update on J&J MedTech’s launch of the Ottava soft-tissue robotic surgery system and Barnaby Pickering talks about his recent interview with Leo Grady, former CEO of Paige AI, to talk about his new start-up Jona. Medtech Insight articles addressing topics discussed in this episode: Can Digital Twin Technology Help Beat Chronic Disease? Twin Health Is Getting Users Hooked, And Off Their Meds https://medtech.citeline.com/MT148407/Can-Digital-Twin-Technology-Help-Beat-Chronic-Disease-Twin-Health-Is-Getting-Users-Hooked-And-Off-Their-Meds Abbott’s Metabolic Biowearable Gets ‘Extremely Positive’ UK Reception; Next Up, US Filing https://medtech.citeline.com/MT148365/Abbotts-Metabolic-Biowearable-Gets-Extremely-Positive-UK-Reception-Next-Up-US-Filing After Two-Year Delay, J&J Plans To Start Trial Ottava Surgical Robot In 2024 https://medtech.citeline.com/MT148422/After-TwoYear-Delay-JJ-Plans-To-Start-Trial-Ottava-Surgical-Robot-In-2024 Leo Grady’s Jona Hopes To Repair Microbiome Testing’s Murky Reputation https://medtech.citeline.com/MT148403/Leo-Gradys-Jona-Hopes-To-Repair-Microbiome-Testings-Murky-Reputation Investing In Digital: Slow And Steady May Win This Race https://invivo.citeline.com/IV148596/Investing-In-Digital-Slow-And-Steady-May-Win-This-Race

Audio roundup of selected biopharma industry content from Scrip over the past business week. In this episode: AstraZeneca CEO on obesity and more; biotech’s rollercoaster ride set to continue; new Wegovy data; Novo’s plans for semaglutide in NASH; and Zepbound set to become biggest drug ever? https://scrip.citeline.com/SC149388/Quick-Listen-Scrips-Five-MustKnow-Things

Pink Sheet reporters and editors discuss US FDA Principal Deputy Commissioner Janet Woodcock’s legacy as her retirement approaches (:42), the stance of the FDA’s oncology division on confirming benefit after an accelerated approval (16:59), and why formal meetings between the agency and sponsors cannot be recorded (36:51). More On These Topics From The Pink Sheet With Woodcock’s Retirement, US FDA Loses A Renaissance Woman: https://pink.citeline.com/PS149368/With-Woodcocks-Retirement-US-FDA-Loses-A-Renaissance-Woman Confirmatory Trial Plan For Acrotech’s Folotyn, Beleodaq Needs Rethinking, FDA Panel Says: https://pink.citeline.com/PS149361/Confirmatory-Trial-Plan-For-Acrotechs-Folotyn-Beleodaq-Needs-Rethinking-FDA-Panel-Says FDA Panel To Consider Strategies For Timely Completion Of Accelerated Approval Confirmatory Trials: https://pink.citeline.com/PS149353/FDA-Panel-To-Consider-Strategies-For-Timely-Completion-Of-Accelerated-Approval-Confirmatory-Trials Accelerated Approval: US FDA Writing Guidance On What ‘Ongoing’ Means For Confirmatory Trials: https://pink.citeline.com/PS149359/Accelerated-Approval-US-FDA-Writing-Guidance-On-What-Ongoing-Means-For-Confirmatory-Trials Accelerated Approval: Acrotech’s Confirmatory Trial For Folotyn, Beleodaq More Than A Decade Behind Schedule: https://pink.citeline.com/PS149342/Accelerated-Approval-Acrotechs-Confirmatory-Trial-For-Folotyn-Beleodaq-More-Than-A-Decade-Behind-Schedule Minutes Matter: Why The US FDA Refuses To Record Formal Meetings: https://pink.citeline.com/PS149310/Minutes-Matter-Why-The-US-FDA-Refuses-To-Record-Formal-Meetings

Syngene’s MD & CEO, Jonathan Hunt, in an interview with Scrip, dissects trends and opportunities in the CRDMO segment as US biotechs slow their burn rate amid a funding squeeze while other large and medium-sized biopharma firms seek to rebalance their supply chain. The Indian firm’s ability to add value in the development and manufacture of ADCs and also its partnership with Amgen are some of the other topics the ex-AstraZeneca executive discusses.

Audio roundup of selected biopharma industry content from Scrip over the past business week. In this episode: US approval for Lilly’s obesity drug; a look at the future of the obesity market; BMS’s ADC deal; Roche’s MS plans; and one Chinese firm’s CAR-T plans. https://scrip.citeline.com/SC149349/Quick-Listen-Scrips-Five-MustKnow-Things

Pink Sheet reporter and editors discuss the FTC’s challenges of Orange Book patents (:35), DTC promotion practices as part of acquisition due diligence (12:39), and how Intarcia’s advisory committee decision appeal could play out (19:06). More On These Topics From The Pink Sheet In Swift Challenge To Orange Book Patent Listings, Federal Trade Commission Fills FDA Ministerial Gap: https://pink.citeline.com/PS149316/In-Swift-Challenge-To-Orange-Book-Patent-Listings-Federal-Trade-Commission-Fills-FDA-Ministerial-Gap Rx Ad/Promo Practices Should Be Part Of Acquisition Due Diligence, DoJ Official Says: https://pink.citeline.com/PS149309/Rx-AdPromo-Practices-Should-Be-Part-Of-Acquisition-Due-Diligence-DoJ-Official-Says Intarcia Appeals Advisory Committee On Diabetes Drug-Device Combo, Claiming ‘Misrepresentation’: https://pink.citeline.com/PS149311/Intarcia-Appeals-Advisory-Committee-On-Diabetes-DrugDevice-Combo-Claiming-Misrepresentation

In this episode, HBW Insight speaks to Simon-Kucher & Partners about the latest trends in preventative consumer health. Partner Christian Rebholz and senior director Lorenzo Eandi explain the findings from the company’s recently published Better Health Report, which reached out to almost 3,000 consumers from across the world. We take a deeper dive into Brazil, where consumers are spending more on than average on preventative health, and Germany, where consumers are spending less but are turning to digital tools thanks to government support. We also find out what consumer health companies can do to respond to a growing awareness of mental health, especially among women and the younger generation.

Humira Biosimilar Landscape Other platforms Apple Podcasts - https://podcasts.apple.com/us/podcast/pharma-intelligence-podcasts/id923189836 Google Podcasts - https://podcasts.google.com/feed/aHR0cHM6Ly9mZWVkcy5zb3VuZGNsb3VkLmNvbS91c2Vycy9zb3VuZGNsb3VkOnVzZXJzOjEwNjU1NDkyOC9zb3VuZHMucnNz TuneIn - https://tunein.com/podcasts/Business--Economics-Podcasts/Pharma-Intelligence-Podcasts-p1140128/ Spotify Podcasts - https://open.spotify.com/show/3DTc3eIh4xI6pVOd6DdO67

일본 최대 제약바이오 R&D 허브와 한국 바이오벤처들이 세포유전자치료제 분야의 협업을 활발히 추진하고 있다는 Scrip 기사를 요약한 내용입니다. https://scrip.citeline.com/SC149214/Japans-Largest-Biocluster-Korean-Ventures-To-Collaborate-For-Cell-And-Gene-Therapies

Audio roundup of selected biopharma industry content from Scrip over the past business week. In this episode: CEOs on global tensions; Roche’s new Alzheimer's contender; Sanofi eyes external deals; investors’ reactions to clinical data; and Korean licensing pitfalls https://scrip.citeline.com/SC149308/Quick-Listen-Scrips-Five-MustKnow-Things

Pink Sheet reporters and editor discuss take-aways from the first Medicare price negotiation program public listening sessions (:35), next steps after Sarepta reported questionable top-line data for its Duchenne muscular dystrophy gene therapy Elevidys (14:45), and indications the FDA may adjust its regulatory approach to gene editing products (26:27). More On These Topics From The Pink Sheet Could Government Negotiated Prices Curtail Access? PBMs And Potential Perverse Incentives Dominate First Medicare Listening Session: https://pink.citeline.com/PS149097/Could-Government-Negotiated-Prices-Curtail-Access-PBMs-And-Potential-Perverse-Incentives-Dominate-First-Medicare-Listening-Session Elevidys And The EMBARK Trial: Is Another Advisory Committee Meeting Coming? https://pink.citeline.com/PS149282/Elevidys-And-The-EMBARK-Trial-Is-Another-Advisory-Committee-Meeting-Coming US FDA’s Confidence In Gene Editing Safety Growing Enough That Regulatory Bar May Be Lowered: https://pink.citeline.com/PS149289/US-FDAs-Confidence-In-Gene-Editing-Safety-Growing-Enough-That-Regulatory-Bar-May-Be-Lowered Heritable Genetic Modification Debate May Ignite Again As Technology Advances: https://pink.citeline.com/PS149098/Heritable-Genetic-Modification-Debate-May-Ignite-Again-As-Technology-Advances